Targeted delivery of anti-cancer drug sorafenib through magnetic solid lipid nanoparticles
Grillone A., Redolfi Riva E., Moscato S., Sacco R., Mattoli V., Ciofani G., Italian Institute of Technology, IT
The multi-kinase inhibitor sorafenib (tradename Nexavar®, Bayer) has been recently approved by the FDA for the treatment of non-resectable hepatocarcinoma and advanced renal carcinoma. Despite its proven survival benefit, sorafenib can lead to important side [...]